10x Genomics Inc. Class A (TXG)
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 76.23 +0.17%
TXG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.92B
- Forward P/E
- 992.57
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 11.16 – 102.81
- Day range
- 73.00 – 82.72
- Volume / Avg
- 9.37M / 3.15M
- Beta
- —
- Shares outstanding
- 120.21M
- Next earnings
- Nov 5, 2026
52-week range
TXG stock today
10x Genomics (TXG) closed at $76.10 on Oct 7, down 5.65% (-$4.56), versus the S&P 500's 0.22% decline. Volume was 3.0x the average at 9.37M shares, a sign of unusually heavy trading. Shares are 26.0% below their 52-week high of $102.81, set on Oct 6, 2026 and 581.9% above the 52-week low of $11.16, in the middle of the past year's range.
TXG is up 366.6% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 556.0%. 10x Genomics has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful. 10x Genomics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About 10x Genomics
Company profile10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Serge Saxonov Ph.D.
- Headquarters
- Pleasanton, CA
- Employees
- 1,178
- IPO year
- 2019
- Website
- 10xgenomics.com
Financial highlights
Full financialsIn fiscal 2025, 10x Genomics generated $642.8 million in revenue, up 5.2% from fiscal 2024. 10x Genomics reported a net loss of $43.5 million, compared with a loss of $182.6 million a year earlier. Gross margin was 69.1% (up from 67.9%) and operating margin -9.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $642.82M | $610.78M | $618.73M | $516.41M | $490.49M |
| Growth | +5.25% | -1.28% | +19.81% | +5.28% | +64.13% |
| Net income | $-43.54M | $-182.63M | $-255.10M | $-166.00M | $-58.22M |
| EPS (diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
Analyst forecast
ForecastConsensus (19 analysts)
buy
Avg. price target
$66.00-13.27%
- Strong buy 1
- Buy 6
- Hold 12
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.27
- Last reported (Q2 2026)
- Aug 7, 2026
- EPS actual vs est.
- $-0.14 vs —
TXG news
All TXG news10x Genomics peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTRAvantor Inc. | 15.35 | -0.52% | $10.38B | vs TXG |
| BIOBio-Rad Laboratories Inc. Class A | 367.92 | -0.25% | $9.84B | vs TXG |
| BRKRBruker Corporation | 59.72 | -1.29% | $9.10B | vs TXG |
| RVTYRevvity Inc. | 153.60 | +0.20% | $17.14B | vs TXG |
| ALMRAlamar Biosciences Inc. | 27.77 | -13.92% | $1.93B | vs TXG |
| PACBPacific Biosciences of California Inc. | 2.72 | +0.74% | $845.46M | vs TXG |
| CTKBCytek Biosciences Inc. | 5.34 | -0.74% | $694.11M | vs TXG |
| EYPTEyePoint Inc. | 3.32 | +4.73% | $278.35M | vs TXG |
Indexes, lists and sector
10x Genomics stock FAQ
What is 10x Genomics's stock price today?
TXG last traded at $76.10 as of Oct 7, 4:00 PM EDT, down 5.65% on the day. Prices are delayed at least 15 minutes.
When is 10x Genomics's next earnings date?
10x Genomics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.27.
Who is 10x Genomics's CEO?
Dr. Serge Saxonov Ph.D. is the chief executive officer of 10x Genomics Inc. Class A, which has about 1,178 employees.
What is the TXG 52-week high?
The 52-week high for TXG is $102.81 and the 52-week low is $11.16. The stock is currently 26.0% below its high.